The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells. In the phase 2 part of a ...
Stocktwits on MSN
Exicure stock soars 40% after stem cell drug helps most patients hit phase 2 goal — traders call it 'cheap' at current levels
Phase 2 data showed rapid increases in CD34+ stem cells, allowing same-day dosing and collection. ・Daratumumab-treated patients, who often struggle with mobilization, also achieved strong collection ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback